NHS wasting hundreds of millions of pounds says Marsh

Speaking at a conference examining healthcare acquired infections (HAIs), Robert Wendin, Head of Marsh’s Healthcare Practice for Europe, the Middle East and Africa, said that hospitals which invest in MRSA prevention can demonstrate tangible financial returns.

Mr Wendin said: “The moral duty to patients already provides a clear reason to tackle MRSA. Our analysis shows that there is now a strong financial one as well. “We calculate that HAIs can cost an average 300-bed hospital over £1.5 million

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected].

You are currently unable to copy this content. Please contact [email protected] to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Insurance Age? View our subscription options

If you already have an account, please sign in here.

You need to sign in to use this feature. If you don’t have an Insurance Age account, please register now.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: